The stock of Pearson plc ADR (PSO) has seen a 0.56% increase in the past week, with a -7.76% drop in the past month, and a -0.50% decrease in the past quarter. The volatility ratio for the week is 1.27%, and the volatility levels for the past 30 days are at 1.27% for PSO. The simple moving average for the last 20 days is -1.02% for PSO’s stock, with a simple moving average of 8.51% for the last 200 days.
Is It Worth Investing in Pearson plc ADR (NYSE: PSO) Right Now?
The price-to-earnings ratio for Pearson plc ADR (NYSE: PSO) is above average at 19.73x, Company’s 36-month beta value is 0.61.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PSO is 679.22M, and currently, short sellers hold a 0.11% ratio of that floaft. The average trading volume of PSO on April 03, 2025 was 513.90K shares.
PSO) stock’s latest price update
Pearson plc ADR (NYSE: PSO)’s stock price has gone decline by -0.19 in comparison to its previous close of 16.07, however, the company has experienced a 0.56% increase in its stock price over the last five trading days. globenewswire.com reported 2025-04-03 that MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatr i c Designation granted MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy HAIFA, Israel, April 03, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its second Investigational New Drug (IND) application for MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. The IND supports the initiation of a Phase I I clinical trial of MNV-201 in pediatric patients with Pearson Syndrome, a primary mitochondrial disease.
PSO Trading at -3.07% from the 50-Day Moving Average
After a stumble in the market that brought PSO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.39% of loss for the given period.
Volatility was left at 1.27%, however, over the last 30 days, the volatility rate increased by 1.27%, as shares sank -3.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.23% upper at present.
During the last 5 trading sessions, PSO rose by +0.60%, which changed the moving average for the period of 200-days by +33.49% in comparison to the 20-day moving average, which settled at $16.20. In addition, Pearson plc ADR saw -0.50% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PSO
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.51 for the gross margin
The net margin for Pearson plc ADR stands at 0.1. The total capital return value is set at 0.09. Equity return is now at value 10.99, with 6.46 for asset returns.
Based on Pearson plc ADR (PSO), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at 0.61. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 4.91.
Currently, EBITDA for the company is 1.11 billion with net debt to EBITDA at 1.07. When we switch over and look at the enterprise to sales, we see a ratio of 2.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.85.
Conclusion
In a nutshell, Pearson plc ADR (PSO) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
